Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Carl Zeiss Meditec AG (AFX.DE)
Jena, TH, DE
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +12.36% | +12.54% | +9.37% | +7.08% | -34.16% | -27.44% | -56.42% | -74.45% | -79.28% | -11.41% | +12.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 13 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+7.8% Q1'26: +102.0% (vs Q4'24)
-
EPS growth Medical - Specialties: +10.1%-19.9% Q1'26: -5.6% (vs Q4'24)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+8.7% Q1'26: +9.0% (vs Q4'24)
-
EBIT margin Medical - Specialties: +12.6%+9.9% Q1'26: +3.7% (vs Q4'24)
-
ROIC Medical - Specialties: +6.6%+6.0% Q1'26: +3.6% (vs Q4'24)
-
Share dilution Medical - Specialties: 0.0%-1.5% ★ Q1'26: +0.4% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×1.75× Q1'26: 1.36× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2011 actual |
Sep 2012 actual |
Sep 2013 actual |
Sep 2014 actual |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 12 Rev. Ana. 10 EPS Ana. |
Sep 2027 14 Rev. Ana. 12 EPS Ana. |
Sep 2028 12 Rev. Ana. 12 EPS Ana. |
Sep 2029 10 Rev. Ana. 9 EPS Ana. |
Sep 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
758.79M
est: 759.22M (-0.1%)
|
861.88M
est: 871.75M (-1.1%)
|
906.45M
est: 906.28M (+0.0%)
|
909.26M
est: 931.03M (-2.3%)
|
1.04B
est: 1.01B (+3.1%)
|
1.09B
est: 1.10B (-1.1%)
|
1.19B
est: 1.18B (+1.3%)
|
1.28B
est: 1.29B (-0.5%)
|
1.46B
est: 1.44B (+1.1%)
|
1.34B
est: 1.35B (-1.3%)
|
1.65B
est: 1.65B (-0.1%)
|
1.90B
est: 1.83B (+3.7%)
|
2.09B
est: 2.06B (+1.3%)
|
2.07B
est: 2.07B (-0.2%)
|
2.23B
est: 2.20B (+1.3%)
|
2.21B
2.11B – 2.29B
+0.4% YoY
|
2.33B
2.19B – 2.53B
+5.5% YoY
|
2.48B
2.47B – 2.49B
+6.3% YoY
|
2.66B
2.53B – 2.82B
+7.4% YoY
|
2.83B
2.68B – 3.00B
+6.2% YoY
|
| EBITDA |
127.06M
est: 102.28M (+24.2%)
|
136.96M
est: 128.60M (+6.5%)
|
167.67M
est: 128.29M (+30.7%)
|
134.48M
est: 178.55M (-24.7%)
|
133.88M
est: 134.32M (-0.3%)
|
165.15M
est: 105.20M (+57.0%)
|
214.47M
est: 160.43M (+33.7%)
|
212.52M
est: 241.41M (-12.0%)
|
285.88M
est: 212.52M (+34.5%)
|
266.41M
est: 231.68M (+15.0%)
|
409.21M
est: 262.68M (+55.8%)
|
482.36M
est: 280.18M (+72.2%)
|
502.77M
est: 450.93M (+11.5%)
|
403.06M
est: 450.22M (-10.5%)
|
346.89M
est: 480.87M (-27.9%)
|
483.04M
462.21M – 499.87M
+0.4% YoY
|
509.75M
479.45M – 552.26M
+5.5% YoY
|
542.06M
540.46M – 543.66M
+6.3% YoY
|
582.16M
552.18M – 616.93M
+7.4% YoY
|
618.47M
586.63M – 655.41M
+6.2% YoY
|
| EBIT |
108.12M
est: 96.60M (+11.9%)
|
122.26M
est: 118.96M (+2.8%)
|
149.68M
est: 127.77M (+17.1%)
|
117.48M
est: 137.56M (-14.6%)
|
104.50M
est: 132.13M (-20.9%)
|
145.56M
est: 141.64M (+2.8%)
|
191.25M
est: 165.81M (+15.3%)
|
181.84M
est: 198.66M (-8.5%)
|
238.07M
est: 220.21M (+8.1%)
|
206.61M
est: 252.43M (-18.2%)
|
348.42M
est: 286.21M (+21.7%)
|
413.08M
est: 305.27M (+35.3%)
|
427.81M
est: 355.87M (+20.2%)
|
270.29M
est: 355.35M (-23.9%)
|
220.52M
est: 379.50M (-41.9%)
|
381.21M
364.77M – 394.50M
+0.4% YoY
|
402.29M
378.38M – 435.84M
+5.5% YoY
|
427.79M
426.53M – 429.05M
+6.3% YoY
|
459.43M
435.78M – 486.88M
+7.4% YoY
|
488.09M
462.96M – 517.25M
+6.2% YoY
|
| Net Income |
72.27M
est: 61.17M (+18.2%)
|
71.87M
est: 76.82M (-6.4%)
|
93.51M
est: 74.75M (+25.1%)
|
74.95M
est: 96.05M (-22.0%)
|
62.30M
est: 82.10M (-24.1%)
|
98.33M
est: 67.57M (+45.5%)
|
134.45M
est: 105.64M (+27.3%)
|
126.46M
est: 147.70M (-14.4%)
|
159.76M
est: 141.27M (+13.1%)
|
122.39M
est: 152.37M (-19.7%)
|
236.28M
est: 172.76M (+36.8%)
|
293.91M
est: 184.27M (+59.5%)
|
290.40M
est: 261.22M (+11.2%)
|
178.73M
est: 155.88M (+14.7%)
|
141.21M
est: 153.27M (-7.9%)
|
131.98M
121.37M – 142.59M
-13.9% YoY
|
159.03M
94.70M – 208.38M
+20.5% YoY
|
188.52M
158.03M – 212.42M
+18.5% YoY
|
242.82M
226.57M – 261.67M
+28.8% YoY
|
279.05M
260.38M – 300.72M
+14.9% YoY
|
| SGA |
227.42M
est: 222.84M (+2.1%)
|
245.01M
est: 261.11M (-6.2%)
|
256.61M
est: 254.70M (+0.7%)
|
267.92M
est: 263.61M (+1.6%)
|
297.14M
est: 293.27M (+1.3%)
|
301.81M
est: 322.28M (-6.4%)
|
337.65M
est: 324.25M (+4.1%)
|
353.65M
est: 370.93M (-4.7%)
|
393.91M
est: 395.04M (-0.3%)
|
349.16M
est: 375.71M (-7.1%)
|
363.98M
est: 425.98M (-14.6%)
|
438.06M
est: 454.36M (-3.6%)
|
504.06M
est: 515.18M (-2.2%)
|
569.21M
est: 514.38M (+10.7%)
|
626.52M
est: 549.40M (+14.0%)
|
551.87M
528.07M – 571.10M
+0.4% YoY
|
582.39M
547.77M – 630.96M
+5.5% YoY
|
619.30M
617.48M – 621.13M
+6.3% YoY
|
665.11M
630.87M – 704.84M
+7.4% YoY
|
706.60M
670.22M – 748.81M
+6.2% YoY
|
| EPS |
0.82
est: 0.83 (-1.0%)
|
0.88
est: 0.91 (-3.1%)
|
1.13
est: 1.13 (+0.3%)
|
0.92
est: 1.01 (-9.0%)
|
0.77
est: 0.97 (-20.5%)
|
1.21
est: 1.18 (+2.3%)
|
1.57
est: 1.44 (+9.3%)
|
1.41
est: 1.48 (-4.5%)
|
1.79
est: 1.97 (-9.0%)
|
1.37
est: 1.28 (+7.2%)
|
2.64
est: 2.78 (-4.9%)
|
3.29
est: 2.84 (+16.0%)
|
3.25
est: 2.93 (+11.0%)
|
2.01
est: 1.84 (+9.1%)
|
1.61
est: 1.74 (-7.6%)
|
1.49
1.39 – 1.63
-14.3% YoY
|
1.88
1.08 – 2.38
+26.3% YoY
|
2.24
1.81 – 2.43
+19.1% YoY
|
2.77
2.59 – 2.99
+23.6% YoY
|
3.19
2.97 – 3.44
+14.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Justus Felix Wehmer | Chief Financial Officer & Member of the Management Board | 661.0K | male |
| Christian Munster | Head of Global Regulatory & Clinical Affairs, CoCe Site Jena & Emp. Rep. Member of Supervisory Board | 41.0K | — |
| Euan S. Thomson | President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit | — | — |
| Eva-Maria Heine | Chief Human Resources Officer | — | — |
| Magnus Reibenspiess | Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technology | — | male |
| Sebastian Frericks | Director of Investor Relations | — | male |
| Stefanie Spanagel | Chief Operating Officer | — | — |
| Andreas Pecher | Interim Chairman of the Management Board & Interim CEO | — | male |
| Steven C. Schallhorn | Chief Medical Officer for Global Ophthalmic Devices | — | male |
| Andrew Chang | Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec, Inc. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AFX.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
